SCHEMBL1103520

SCHEMBL1103520

c1ccc(-c2ccc3ccccc3c2-c2c3ccccc3c(-c3ccc4ccccc4c3)c3c2cnc2ccccc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MET P08581 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ PIK3CD O00329 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CB P42338 1/20 0.37
▸ MTOR P42345 1/20 0.37
▸ PIK3CG P48736 1/20 0.37
▸ ESR1 P03372 2/20 0.36
▸ ESR2 Q92731 2/20 0.36
▸ CYP1A1 P04798 1/20 0.35
▸ CYP1B1 Q16678 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103405 0.91 MAPT (0.46) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103503 0.90 MET (0.41) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103268 0.90 MAPT (0.47) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103459 0.89 ESR1 (0.41) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103521 0.88 SMN1; SMN2 (0.40) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103506 0.88 MET (0.43) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103448 0.87 ESR1 (0.48) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103484 0.87 ESR1 (0.48) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103381 0.87 ESR1 (0.48) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL1103493 0.87 ESR1 (0.48) MAPTSMN1; SMN2NPC1LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MAPT 3162/4885SMN1; SMN2 4091/4885NPC1 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback